Introduction: Vaccination of children has experienced delays due to paucity of information regarding safety, effectiveness, immunogenicity, and reactogenicity. Age wise approval prioritized 12 - 17 years and later 5 -...Introduction: Vaccination of children has experienced delays due to paucity of information regarding safety, effectiveness, immunogenicity, and reactogenicity. Age wise approval prioritized 12 - 17 years and later 5 - 11 years. Those below 5 years possess na?ve immunity and not considered. In Lake Region Economic Bloc children aged 12 - 17 variably received 1, 2, and 3 doses of vaccine. This analysis looks into effectiveness of the doses administered. Method: Data providers from 84 LREB facilities submitted patients’ vaccination data to Power BI supported dashboard between June 24, 2021 and July 30, 2022. Data of 12 - 17 years old was mined, analyzed and visualized. Sample sizes considered for analysis were 0 dose, n = 8132;1 dose, n = 271;2 doses, n = 402, and 3 doses, n = 90. Data used in the analysis was facility operational and not from experimental design. Relative risk analysis of children who received 0, 1, 2, and 3 doses was done using Odds Ratio run on R software. Results: The relative risk of infection to a child with one dose against unvaccinated counterpart is 0.92 (95% CI, 0.61 - 1.43). Likewise the relative risk of infection to a child aged 12 - 17 years with 2 doses against another who received no dose is 0.87 (95% CI, 0.63 - 1.24). A child with 3 doses is 46% (95% CI, 27% - 84%) less likely to get infected compared to another not vaccinated. Also, the relative risk between having 2 doses and 1 dose for a child aged 12 - 17 years is 0.95 (95% CI, 0.55 - 1.6). For the same age group the relative risk of having 3 doses of vaccines against 1 dose is 51% (95% CI, 26% - 100%). In addition, a child who receives 3 doses of vaccine is 53% (95% CI, 28% - 100%) less likely to experience breakthrough infection compared to another with 2 doses. Whereas 1<sup>st</sup> dose offers (5%) marginal protection advantage over the 2<sup>nd</sup> dose, the 3r dose offers 49% and 47% more protection over 1<sup>st</sup> and 2<sup>nd</sup> doses, respectively, because of incremental reduced risk of infection gained from previous doses. During the period, 15 children at risk were admitted with COVID-19 infections in various regional hospitals, one had 3 doses but confounded with severe comorbidity. Conclusion: We found that 2<sup>nd</sup> dose had marginal protection over the 1<sup>st</sup> dose. However, the 3<sup>rd</sup> dose offers extensive protection compared to 1<sup>st</sup> and 2<sup>nd</sup> doses, and protects more against hospitalization. Children at risk should receive 3 doses of vaccines.展开更多
文摘Introduction: Vaccination of children has experienced delays due to paucity of information regarding safety, effectiveness, immunogenicity, and reactogenicity. Age wise approval prioritized 12 - 17 years and later 5 - 11 years. Those below 5 years possess na?ve immunity and not considered. In Lake Region Economic Bloc children aged 12 - 17 variably received 1, 2, and 3 doses of vaccine. This analysis looks into effectiveness of the doses administered. Method: Data providers from 84 LREB facilities submitted patients’ vaccination data to Power BI supported dashboard between June 24, 2021 and July 30, 2022. Data of 12 - 17 years old was mined, analyzed and visualized. Sample sizes considered for analysis were 0 dose, n = 8132;1 dose, n = 271;2 doses, n = 402, and 3 doses, n = 90. Data used in the analysis was facility operational and not from experimental design. Relative risk analysis of children who received 0, 1, 2, and 3 doses was done using Odds Ratio run on R software. Results: The relative risk of infection to a child with one dose against unvaccinated counterpart is 0.92 (95% CI, 0.61 - 1.43). Likewise the relative risk of infection to a child aged 12 - 17 years with 2 doses against another who received no dose is 0.87 (95% CI, 0.63 - 1.24). A child with 3 doses is 46% (95% CI, 27% - 84%) less likely to get infected compared to another not vaccinated. Also, the relative risk between having 2 doses and 1 dose for a child aged 12 - 17 years is 0.95 (95% CI, 0.55 - 1.6). For the same age group the relative risk of having 3 doses of vaccines against 1 dose is 51% (95% CI, 26% - 100%). In addition, a child who receives 3 doses of vaccine is 53% (95% CI, 28% - 100%) less likely to experience breakthrough infection compared to another with 2 doses. Whereas 1<sup>st</sup> dose offers (5%) marginal protection advantage over the 2<sup>nd</sup> dose, the 3r dose offers 49% and 47% more protection over 1<sup>st</sup> and 2<sup>nd</sup> doses, respectively, because of incremental reduced risk of infection gained from previous doses. During the period, 15 children at risk were admitted with COVID-19 infections in various regional hospitals, one had 3 doses but confounded with severe comorbidity. Conclusion: We found that 2<sup>nd</sup> dose had marginal protection over the 1<sup>st</sup> dose. However, the 3<sup>rd</sup> dose offers extensive protection compared to 1<sup>st</sup> and 2<sup>nd</sup> doses, and protects more against hospitalization. Children at risk should receive 3 doses of vaccines.
